Age-related macular degeneration (AMD) is a leading cause of severe visual loss in the elderly. A long path of clinical trials with various treatment modalities has led to novel contemporary treatments, including bevacizumab (Avastin®; Genentech, CA, USA) and ranibizumab (Lucentis ®; Genentech). These drugs have revolutionized the approach to neovascular AMD, and today they are one of the major treatments for the disease. While both these drugs are reported to be effective, with somewhat stronger clinical evidence for ranibizumab, debate continues as to which is most effective in the treatment of AMD. Large-scale studies currently underway are expected to shed light on the subject. Based on the evolving data, as well as on our clinical experience, we believe that the two drugs, while harboring different biological characteristics and potential clinical differences, still share many similar characteristics in their efficacy and safety. The similarities and differences in efficacy and safety will be demonstrated in prospective comparative trials currently taking place.
- age-related macular degeneration
- neovascular maculopathy
- vascular endothelial growth factor